INBS · Intelligent Bio Solutions Inc.

The update to shares outstanding reflects incremental equity issuance since the prior 8-K filed on March 23, 2026, driven by two disclosed sources: (i) exercises of previously issued warrants to purchase common stock, and (ii) sales of common stock under the At The Market Offering Agreement dated September 18, 2024, with Ladenburg Thalmann & Co. Inc. While no pricing, proceeds, or warrant exercise volume is disclosed, the resulting total of 2,176,848 outstanding shares represents a quantifiable dilutive event for existing shareholders. This disclosure falls under Item 8.01 — Other Events — and is not accompanied by financial results, management commentary, or forward-looking guidance in the main filing text; Exhibit 99.1 (the investor presentation) is referenced but not provided here, so no operational or strategic context beyond the share count change can be extracted. Investors should note that this update does not indicate a new financing round or material agreement beyond the pre-existing ATM program, nor does it signal changes to capital structure, liquidity, or control.